Atturos
Clinical diagnostics company spun out from University College Dublin developing targeted proteomic diagnostic tests. Core activities include targeted mass spectrometry assay development, biomarker discovery and validation, clinical assay transfer and in‑house validation, and machine‑learning analytics to produce clinically interpretable scores. The company operates a laboratory at the UCD Conway Institute and participates in multi‑partner European research consortia.
Industries
Nr. of Employees
small (1-50)
Products
RAPsA Dx
Serum protein diagnostic assay intended to discriminate patients with psoriatic arthritis from those with rheumatoid arthritis; performance data reported in peer‑reviewed publication(s).
OCPro Dx
Multi‑protein blood test designed to provide information on organ‑confined prostate cancer to support clinical decision making; early clinical data reported and commercialization planning ongoing.
PromarkerD
Blood test assessing risk of diabetic kidney disease in type 2 diabetes by measuring a panel of plasma biomarkers combined with clinical factors; method transferred to the company for local validation and European launch planning.
RAPsA Dx
Serum protein diagnostic assay intended to discriminate patients with psoriatic arthritis from those with rheumatoid arthritis; performance data reported in peer‑reviewed publication(s).
OCPro Dx
Multi‑protein blood test designed to provide information on organ‑confined prostate cancer to support clinical decision making; early clinical data reported and commercialization planning ongoing.
PromarkerD
Blood test assessing risk of diabetic kidney disease in type 2 diabetes by measuring a panel of plasma biomarkers combined with clinical factors; method transferred to the company for local validation and European launch planning.
Services
Assay development and validation services
Design, optimisation and clinical validation of targeted multiplexed proteomic assays for blood biofluids; includes method transfer into the company laboratory.
Collaborative research and consortium participation
Operational participation in multi‑partner EU and industry consortia to develop and evaluate biomarkers, sampling methods and in vitro testing approaches.
Assay development and validation services
Design, optimisation and clinical validation of targeted multiplexed proteomic assays for blood biofluids; includes method transfer into the company laboratory.
Collaborative research and consortium participation
Operational participation in multi‑partner EU and industry consortia to develop and evaluate biomarkers, sampling methods and in vitro testing approaches.
Expertise Areas
- Targeted proteomics and mass spectrometry
- Multiplexed proteomic assay development
- Biomarker discovery and clinical translation
- Clinical evaluation and validation of diagnostics
Key Technologies
- Targeted mass spectrometry (MRM)
- Immunoaffinity enrichment for proteomics
- Isotopically labelled internal standards
- Multiplexed protein assays